Abstract:

Objectives: Asprosin is a newly identified adipokine which is involved in glucose and lipid metabolisms as well as inflammation. Type 2 diabetes mellitus T2DM associated with dysfunctions in glucose and lipid metabolisms is known as a metabolic disorder. The aim of this study was to investigate whether asprosin levels were changed in subjects with newly diagnosed T2DM nT2DM comparing to subjects with normal glucose tolerance NGT and to determine if asprosin levels were linked to metabolic parameters. Method: This case control study included 68 subjects with nT2DM and 68 NGT age-, body mass index BMI - and gender-matched subjects. We used ELISA method for measuring the circulating asprosin levels. A 2-h 75-g oral glucose tolerance test was used for diagnosing of T2DM. Metabolic parameters of enrolled subjects were determined.Results: Circulating asprosin levels were elevated in nT2DM subjects when compared to controls. 6.75 ± 1.54 vs. 4.05 ± 1.28 ng/ml, P < 0.001 . Moreover, asprosin levels were found to be higher in nT2DM subjects with metabolic syndrome comparing to those without metabolic syndrome. Correlation analysis revealed that asprosin levels positively correlated with insulin, fasting blood glucose, insulin resistance and triglycerides whereas it displayed negative correlation with HDL cholesterol in only nT2DM subjects. Linear regression analyses showed an independent association between asprosin and insulin resistance. According to the logistic regression analyses, the subjects with the highest asprosin levels increased the probability of nT2DM prevalence. Conclusions: Increased asprosin levels associated with insulin resistance and unfavorable outcomes of metabolic parameters in subjects with nT2DM

Keywords: